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Abstract
Background: Transient receptor potential canonical (TRPC) channels are non-selective cation channels involved in
receptor-mediated calcium signaling in diverse cells and tissues. The canonical transient receptor potential 6
(TRPC6) has been implicated in several pathological processes, including focal segmental glomerulosclerosis (FSGS),
cardiac hypertrophy, and pulmonary hypertension. The two large cytoplasmic segments of the cation channel play
a critical role in the proper regulation of channel activity, and are involved in several protein-protein interactions.
Results: Here we report that SNF8, a component of the endosomal sorting complex for transport-II (ESCRT-II)
complex, interacts with TRPC6. The interaction was initially observed in a yeast two-hybrid screen using the
amino-terminal cytoplasmic domain of TRPC6 as bait, and confirmed by co-immunoprecipitation from eukaryotic
cell extracts. The amino-terminal 107 amino acids are necessary and sufficient for the interaction. Overexpression of
SNF8 enhances both wild-type and gain-of-function mutant TRPC6-mediated whole-cell currents in HEK293T cells.
Furthermore, activation of NFAT-mediated transcription by gain-of-function mutants is enhanced by overexpression
of SNF8, and partially inhibited by RNAi mediated knockdown of SNF8. Although the ESCRT-II complex functions in
the endocytosis and lysosomal degradation of transmembrane proteins, SNF8 overexpression does not alter the
amount of TRPC6 present on the cell surface.
Conclusion: SNF8 is novel binding partner of TRPC6, binding to the amino-terminal cytoplasmic domain of the
channel. Modulating SNF8 expression levels alters the TRPC6 channel current and can modulate activation of
NFAT-mediated transcription downstream of gain-of-function mutant TRPC6. Taken together, these results identify
SNF8 as a novel regulator of TRPC6.
Keywords: Transient receptor potential, Calcium channel, Protein-protein interaction, Calcineurin-NFAT signaling
Background
Transient receptor potential canonical channel 6 (TRPC6)
is one of seven members of the canonical transient recep-
tor potential (TRPC) family of calcium-permeable cation
channels that allow for an increase in intracellular calcium
following activation of G-protein coupled receptors and
receptor tyrosine kinases [1]. TRPC channel subunits as-
semble to form homo- and/or hetero-tetramers [2]. Each
TRPC subunit contains intracellular amino and carboxyl-
terminal domains flanking six transmembrane domains;
the intracellular sequences host canonical protein-protein
interaction domains, including ankyrin-like repeats and a
coiled-coil region in the amino-terminal cytoplasmic do-
main, and carboxyl-terminal TRP box, CIRB (calmodulin/
IP3 receptor binding) sequence, and a coiled-coil region
[3]. Multiple proteins have been shown to bind to TRPC6,
including BKCa [4], calmodulin [5-7], FKBP12 [8], Fyn [9],
IP3 receptor [7,10], MxA [11], the Na+/K+-ATPase
pump [12], PLCγ [13], podocin [14,15], PTEN [16], and
RNF24 [17]. In addition, TRPC6 channel activity can be
modulated by tyrosine [9,13] and serine/threonine phos-
phorylation [18-21], and by binding of phosphoinositides
[6,22,23]. However, how these various post-translational
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channel activity has not been fully elucidated.
TRPC6 has been implicated in several physiological
and pathophysiological functions in the kidney, heart
and vasculature. Mutations in TRPC6 are a cause of fa-
milial, autosomal-dominant, adult-onset focal segmental
glomerulosclerosis (FSGS), a form of proteinuric renal
disease [15,24], and increased TRPC6 expression has
been observed in acquired proteinuric kidney disease
[25,26]. In contrast, TRPC6-deficient mice show mild
protection against angiotensin II mediated glomerular
damage [27]. The majority of FSGS-associated mutations
appear to be gain-of-function, with increased channel
current amplitudes and reduced current decay having
been reported [15,24,28,29]. As all currently identified
FSGS disease-associated TRPC6 mutations map to the
intracellular domains of the channel, it has been
hypothesized that these mutations may act by disrupt-
ing the binding of regulatory proteins to TRPC6, with
the slit diaphragm protein nephrin proposed as one
such protein [13]. How enhanced TRPC6 activity leads
to renal disease, though, remains unknown. In contrast,
in the heart upregulation of TRPC6 has been linked to
the development of pathologic cardiac hypertrophy
through activation of the calcineurin-NFAT pathway
[30,31]. Finally, examinations of TRPC6-deficient mice
have suggested roles in hypoxic pulmonary vasocon-
striction [32], the development of pulmonary edema in
response to ischemia-reperfusion injury [33], and plate-
let function [34].
To discover novel binding partners of TRPC6, we per-
formed a yeast two-hybrid screen using the amino-
terminal domain of TRPC6 as bait and isolated SNF8 as
a TRPC6 binding partner. SNF8 is the mammalian coun-
terpart to yeast VPS22, a component of the ESCRT-II
endosomal trafficking complex required for the endo-
cytosis and lysosomal degradation of transmembrane
proteins [35-37]. The SNF8-TRPC6 interaction was
mapped to the first 107 residues of the N-terminus of
TRPC6, and was confirmed by co-immunoprecipitation
as well as immunofluorescence microscopy. Addition-
ally, overexpression and RNAi-mediated knockdown of
SNF8 in tissue culture reveals a modulatory effect on
wild-type and mutant TRPC6 channel activity as evi-
denced by whole-cell electrophysiology studies and tran-
scriptional luciferase reporter assays.
Results
SNF8 binds to the amino-terminus of TRPC6 in the Yeast
Two-Hybrid System
The amino-terminal cytoplasmic domain of human
TRPC6 (amino acids 1-406) was used as bait in a yeast
two-hybrid screen to identify potential TRPC6 interact-
ing proteins in a human kidney cDNA library. On the
basis of both nutritional selection and β-galactosidase
activity, 10 clones of SNF8 (also known as EAP30
and VPS22) were isolated; all clones included the
entire coding sequence of SNF8 and varying lengths
of 50 UTR. Full-length SNF8 fused to the Gal4 acti-
vation domain was able to interact with the amino-
terminal cytoplasmic domain, but not the carboxyl-
terminal cytoplasmic domain of TRPC6 in the yeast
two-hybrid system as assessed by growth on histidine
and adenine free media (Figure 1) and β-galactosidase
activity (data not shown). Using truncation mutants of
the amino-terminal of TRPC6, it was found that amino
acids 1-107, containing the sequence prior to the
ankyrin repeats, are necessary and sufficient for this
interaction (Figure 1).
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Figure 1 SNF8 binding to TRPC6 in the two-hybrid assay. A. Yeast carrying the pGBKT7 plasmid encoding for the Gal4 DNA binding domain
fused to the indicated TRPC6 amino acids, and either pGADT7 (encoding for the GAL4 activation domain alone) or pGADT7-SNF8 (expressing
full-length SNF8 fused to the GAL4 activation domain) were grown on high stringency selective media, SD-ade, his, leu, trp (left panel), to assess
for protein-protein interaction, or on SD-leu, trp (right panel) as a control. B. Schematic of TRPC6 structure indicating the location of various
structural domains relative to the TRPC6 constructs used in the yeast-two hybrid assay.
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To confirm that the interaction between TRPC6 and
SNF8 can occur in a cellular context, cells stably expres-
sing FLAG-tagged TRPC6 under a tetracycline inducible
promoter were transfected with HA-tagged SNF8.
TRPC6 was immunoprecipitated with the FLAG M2
monoclonal antibody, and the presence of SNF8 in the
isolated immune complexes was assessed by Western
blot using an anti-HA antibody (Figure 2A). HA-SNF8
was detected in the immunoprecipitated material only
when co-expressed with FLAG-TRPC6. We have
not been able to confirm the interaction by co-
immunoprecipitation of endogenous SNF8 and TRPC6,
but this may be due at least in part due to the limited
availability of high quality antibodies to detect endogen-
ous SNF8 (data now shown) or a relatively low affinity
interaction between the two proteins.
To assess if the interaction between the two proteins
might be influenced by TRPC6 channel activation, cells
co-expressing both proteins were treated with or without
carbachol to activate TRPC6 prior to cell lysis and
immunoprecipitation. No notable difference in the
amount of SNF8 in the immune complexes was seen
upon carbachol stimulation (Figure 2B). This suggests
that channel activity or calcium influx is not required for
the establishment of this interaction.
To further confirm the potential interaction between
SNF8 and TRPC6, the localization of the two overex-
pressed proteins was determined by immunofluores-
cence microscopy. Overall, there was little colocalization
of the two signals, though small punctate regions sug-
gesting areas of colocalization of the two proteins were
seen in most cells examined (Figure 3).
SNF8 enhances TRPC6-mediated current
To address whether SNF8 may play a role in the regula-
tion of TRPC6 activity, we performed electrophysiology
experiments in the whole cell configuration in HEK293T
cells expressing the muscarinic M1 acetylcholine recep-
tor and either TRPC6 and SNF8, or TRPC6 alone. Acti-
vation of the M1 receptor with carbachol resulted in a
whole cell current with a characteristic current-voltage
relationship for TRPC6: a small inward and a steeply
outwardly rectifying component. Co-expression of SNF8
led to increased whole cell current amplitude in both the
inward and outward directions (Figure 4A and C). The
ability of SNF8 to enhance TRPC6-mediated currents
extended to channels containing an FSGS-associated mu-
tation, E897K (Figure 4B and C). This mutation was pre-
viously characterized as a gain-of-function mutation
leading to increased whole cell current amplitude com-
pared to wild-type controls [15].
We attempted to ascertain whether the effect of SNF8
on TRPC6 was dependent on direct binding of the two
proteins. A TRPC6 construct lacking the amino terminal
106 amino acids (FLAG-TRPC6 107-931), required for
SNF8 binding in the two hybrid assay, expressed at sig-
nificantly lower levels than full-length TRPC6, though it
was capable of forming multimers, based on its ability to
co-immunoprecipitate full-length HA-tagged TRPC6
(Figure 5A). However, in contrast to full length TRPC6,
the truncated protein failed to generate current in re-
sponse to OAG stimulation (Figure 5B-D), preventing us
from addressing whether the effect of SNF8 on TRPC6
currents was dependent on binding at this site. Similarly,
TRPC6 107-931 failed to generate significant current
after stimulation with carbachol (data not shown).
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Figure 2 Binding of TRPC6 to SNF8 in 293T cells. A. M1R cells
expressing FLAG-tagged TRPC6 under a tetracycline inducible
promoter were transfected with HA-tagged SNF8 or control vector,
followed by culture in the absence or presence of 1 μg/ml
tetracycline to induce the expression of TRPC6. Cell lysates were
either directly analyzed for TRPC6 and SNF8 expression by Western
blot (top and middle panel, respectively), or incubated with FLAG
M2 affinity beads to immunoprecipitate TRPC6. HA-tagged SNF8
was detected bound to the affinity beads when expressed in the
presence of TRPC6 (bottom panel). B. Cells transfected with
HA-tagged SNF8 and induced to express TRPC6 as indicated were
treated with or without 100 μM carbachol for 5 minutes prior to
lysis and immunoprecipitation as in (A) above.
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transcription downstream of mutant TRPC6
We have previously demonstrated that several FSGS-
associated mutations in TRPC6 lead to activation of
calcineurin-NFAT signaling and NFAT-mediated tran-
scription in the absence of exogenous stimuli [38]. In
light of the ability of SNF8 to enhance TRPC6-mediated
whole cell currents, we examined the ability of SNF8
overexpression to affect TRPC6 mediated activation of
NFAT-mediated transcription (Figure 6A). Overexpres-
sion of SNF8 in cells expressing either the R895C or
E897K mutant TRPC6 channels led to an increase in
NFAT-mediated transcription under unstimulated condi-
tions. In contrast, in cells expressing wild-type TRPC6,
which does not activate NFAT-mediated transcription
under unstimulated conditions, SNF8 overexpression did
not lead to activation of NFAT-driven transcription. Un-
fortunately, known activators of TRPC6, including car-
bachol and OAG, are able to substantially increase
NFAT-mediated transcription in 293T cells even in the
absence of exogenously expressed TRPC6 [38]. There-
fore, we have not been able to ascertain whether overex-
pression of SNF8 is able to enhance NFAT activation by
wild-type TRPC6 after the channel has been activated.
Taken together with the electrophysiologic data, these
results suggest that SNF8 can enhance TRPC6-mediated
currents and downstream signaling pathways, but is not
sufficient to activate the channel.
Most of our current knowledge regarding SNF8 relates
to its function as part of the ESCRT-II complex involved
in transmembrane protein trafficking into multivesicu-
lated bodies [37,39,40]. We therefore hypothesized that
overexpression of SNF8, rather than increasing ESCRT-II
activity, might act in a dominant negative fashion by pro-
viding monomeric SNF8 to compete with intact ESCRT-II
complex for TRPC6 binding. To address this possibility,
we made use of a short hairpin RNA expressing plasmid
to knock down SNF8 protein levels in M1R cells. Introdu-
cing the SNF8 shRNA expressing plasmid into cells
expressing R895C mutant TRPC6 led to a modest de-
crease in activity from an NFAT-responsive luciferase re-
porter construct, compared to cells transfected with a
control shRNA plasmid (Figure 6C). Expression of the
SNF8 shRNA did not significantly alter basal NFAT-
mediated transcription in control cells (WT uninduced
and R895C uninduced) or expressing wild-type TRPC6
(WT induced). Western blot analysis confirmed a decrease
in endogenous SNF8 levels with the SNF8 shRNA
Figure 3 Immunofluorescence localization of TRPC6 and SNF8. M1R cells expressing FLAG-TRPC6 and HA-SNF8 were fixed and stained as
follows: TRPC6 was detected with the anti-FLAG M2 mouse monoclonal antibody and an Alexa488 conjugated anti-mouse secondary (bottom
left); SNF8 was detected with an anti-HA rabbit monoclonal antibody and a Cy3 conjugated anti-rabbit secondary (top right). Nuclei were
counterstained with DAPI (top left). A merged image (bottom right) demonstrates partial localization of TRPC6 and SNF8 in punctuate structures
(arrows). Bar = 10 μm.
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These results suggest that: 1. the effects of overexpressed
SNF8 on TRPC6 channel activity and signaling are not
mediated by a dominant negative effect, and 2. while
SNF8 may enhance TRPC6 activity, it is likely not required
for channel activity given the only modest decrease in
NFAT-reporter activity in response to SNF8 knockdown
in R895C expressing cells. Confirmation of this later point
will require the development of cells completely devoid of
SNF8.
SNF8 overexpression does not alter TRPC6 content on the
cell surface or in detergent resistant membranes
Several TRP channels, including TRPC6, have been
reported to be regulated by altering their cell surface ex-
pression through regulated endo- and exocytosis
[13,41,42]. Mutations in snf8 have been reported to
affect the transport kinetics of Ena1p, a sodium pump in
yeast [43]. We therefore wished to examine whether
SNF8 overexpression might alter TRPC6 function by
modulating the amount of channel expressed on the
plasma membrane. M1R cells were transiently trans-
fected with expression plasmids for FLAG-TRPC6 and
HA-SNF8, either in combination, or alone with control
plasmid. After surface biotinylation of the cells, the
amount of TRPC6 bound to streptavidin beads (repre-
senting cell surface associated protein) was compared to
total TRPC6 in whole cell lysates (Figure 7). Co-
expression of SNF8 did not appreciably alter the amount
of TRPC6 bound to the streptavidin beads compared to
total TRPC6 levels. Interestingly, small amounts of SNF8
could also be detected in material bound to streptavidin
beads (lower panels), consistent with its recruitment to
transmembrane proteins, including plasma membrane
proteins. However, the amount of SNF8 pulled down by
streptavidin beads was not appreciably altered by the
presence or absence of TRPC6, suggesting that cell sur-
face proteins other than TRPC6 were largely responsible
for this effect.
Several TRPC proteins have been reported to partition
into detergent-resistant membranes [44-50], and TPRC1
binds to caveolin-1, a lipid raft-associated protein
Figure 4 SNF8 enhances TRPC6-mediated currents. Whole-cell currents were measured in HEK cells expressing the M1 receptor and
transiently transfected with either wild-type TRPC6 (A) or E897K mutant TRPC6 (B), alone (black line) or with SNF8 (red). Cells were stimulated
with 100 μM carbachol to activate TRPC6-mediated current. C. Average normalized current density in response to carbachol. One way ANOVA
Fisher LSD; ** p value <0.01 vs. TRPC6 WT, ## p value <0.01 between SNF8 and non-SNF8 expressing cells; n=6.
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was reported to shift TRPC1 into lipid rafts, thereby
altering its channel properties [52,54,55]. We therefore
examined whether SNF8 may alter the amount of
TRPC6 present in detergent-resistant membranes. In
control cells, only a very small fraction of TRPC6
(Figure 8A, top panel) was detected in the fractions con-
taining detergent-resistant membranes, as assayed by the
presence of the lipid raft marker caveolin-1 (Figure 8A,
bottom panel), similar to previously reported results
[46,50]. The amount of total TRPC6 found in the low
density fractions did not change appreciably when HA-
SNF8 was overexpressed (Figure 8B). A small amount of
SNF8 was also detected in the detergent resistant mem-
branes (Figure 8B, middle panel). It remains unclear why
caveolin-1 localization peaked in fraction 2, while
TRPC6 and SNF8 in the low density fractions were
mainly in fraction 3, but the generation of distinct lipid
raft subfractions has been reported using a protocol
similar to the one used here [56].
Discussion
Here we identify SNF8 as a novel binding partner of
TRPC6. The interaction was first established in a yeast
two-hybrid screen, where it was found to be mediated
by the amino terminal 107 amino acids of TRPC6. The
TRPC6-SNF8 interaction has been confirmed by co-
immunoprecipitation, and the proteins partially coloca-
lize in cells. Importantly, SNF8 overexpression enhances
whole cell current amplitudes mediated by both wild-
type and FSGS-associated mutant TRPC6, as well as
mutant TRPC6-mediated NFAT activation, while RNAi
mediated knock-down of endogenous SNF8 diminishes
NFAT activation by mutant TRPC6. The effect of SNF8
on TRPC6 channel activity and downstream activation
of NFAT-mediated transcription does not appear to be
mediated by alterations in the global surface expression
levels of TRPC6 or a shift of channel into lipid rafts.
Taken together, these results suggest a novel role for
SNF8 in the modulation of TRPC6 channel activity.
It is difficult to reconcile the ability of SNF8 to en-
hance TRPC6-mediated current with its major known
function, sorting transmembrane proteins into multivesi-
culated bodies for degradation. SNF8, together with
VPS25 and VPS36, forms the endosomal sorting com-
plex for transport (ESCRT) -II complex [35]. ESCRT-II,
in conjunction with the ESCRT-I and –III complexes, is
involved in the budding of intraluminal vesicles from
endosomes to form multivesiculated bodies (MVB)
(reviewed in [37,39,40]). This process is critical for the
downregulation of multiple signaling receptors, includ-
ing the yeast mating receptor Ste2 [35], EGFR[36,57]
and Notch [58,59]. The ESCRT complexes not only tar-
get ubiquitinated transmembrane proteins to the vesicles
100
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D
Figure 5 Amino acids 1-106 are necessary for TRPC6 channel
activity. A. Full-length HA-tagged TRPC6 was expressed together
with the indicated FLAG-tagged TRPC6 constructs in HEK 293T cells.
Expression of FLAG- and HA-tagged protein was confirmed by
Western blot of whole cell lysates (top and middle panels). The
ability of the amino-terminal truncated TRPC6 protein to multimerize
with full-length TRPC6 was confirmed by FLAG immunoprecipitation
followed by western-blotting for HA-TRPC6 (bottom panel). Whole
cell currents in HEK cells transiently transfected with wild-type TRPC6
(B) or TRPC6 107-931 (C) under basal conditions and upon
stimulation with 10 μM OAG. D. Average normalized current density
in response to OAG. One way ANOVA ; * p value < 0.05; n=8 cells.
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ture and ultimate scission of the vesicles from their par-
ent membrane [60-62]. In addition to their role in MVB
formation, ESCRTs are involved in the membrane
scission required for cytokinesis and the budding of
enveloped viruses [63,64].
Whether the endosomal-lysosomal functions of SNF8
might relate to TRPC6 activity is unclear. It is worth
noting that SNF8 has been implicated to have several
non-endosomal functions. These include the establish-
ment of the bicoid mRNA gradient in the Drosophila
oocyte [65] and modulation of the ELL transcription
elongation complex [66]. Perhaps most relevant to its
role in enhancing TRPC6-mediated currents, the yeast
homologue of SNF8, VPS22, as well as other members
of the ESCRT complexes, have been shown to be
involved in the trafficking and surface expression of the
sodium pump Ena1 [43]. Although we have not been
able to detect a change in the amount of total TRPC6
expressed on the cell surface or in lipid rafts in response
to co-expression of SNF8, it is possible that SNF8 traffics
the channel to a subdomain of the plasma membrane
where TRPC6 activity is enhanced. Along these lines, it
is noteworthy that podocin enhances TRPC6 activity in
a cholesterol dependent manner without altering plasma
membrane expression [14], while the differential
FLAG
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Tet - + - + - + - + - + - +
HA-SNF8 + ++ -- -
WT R895C E897K
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D
B
C
SNF8
Actin
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Figure 6 SNF8 effect on NFAT-mediated transcription. A. Cells stably expressing tetracycline-inducible wild-type, R895C or E897K TRPC6 were
transfected with an NFAT-responsive luciferase reporter plasmid and either control plasmid or HA-SNF8 expression plasmid. Normalized luciferase
activity was determined after TRPC6 expression was induced for 24 hours. Results are means ± SEM; one way ANOVA; * p<0.05 vs. control;
***p<0.001 vs. control. B. Western blots to confirm the expression of FLAG-TRPC6 and HA-SNF8 in lysates from cells used in the luciferase assays
in (A). Actin was utilized as a loading control. C. Cells expressing wild-type or R895C TRPC6 under a tetracycline inducible promoter were
transfected with plasmid encoding for either SNF8 shRNA (SNF8 Knockdown) or a scrambled shRNA (control), and luciferase reporter plasmids.
24 hours after transfection, TRPC6 expression was induced by the addition of tetracycline as indicated (induced). Cells cultured in the absence of
tetracycline (uninduced) did not express detectable amounts of TRPC6, and were used as controls. 24 hours post-induction, luciferase reporter
assays were performed. Results are means ± SEM; one way ANOVA, ***p<0.001 vs control shRNA. D. M1R cells were transfected with plasmids
encoding for either an shRNA targeting SNF8, or a scrambled shRNA (control), as well as GFP. 48 hours post-transfection, cells were trypsinized
and GFP expressing cells isolated by FACS cell sorting. Lysates from GFP positive cells were analyzed by Western blot for expression of SNF8.
Actin expression was used as a loading control.
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WB: FLAG
WB: HA
HA-SNF8
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Figure 7 Surface expression of TRPC6. HEK293T cells were
transiently transfected with the indicated combinations of
FLAG-TRPC6 (FLAG-C6) and HA-SNF8 expression plasmids. 48 hours
after transfection, cells were surface biotinylated or mock
biotinylated (-) as indicated and lysed. Biotinylated protein and
associated proteins were isolated by binding to streptavidin agarose
beads. The amounts of TRPC6 and SNF8 in whole lysate (left panel)
and bound to streptavidin beads (right panel) were assessed by
Western blotting.
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coma and leukosis virus (ASLV) and human immuno-
deficiency virus, type-1 (HIV-1), correlates with their
assembly on phosphatidylethanolamine (PE) containing
or PE-negative membranes, respectively [63,67]. Alterna-
tively, it is possible that SNF8 regulates TRPC6 indir-
ectly by competing with a negative regulator or by
altering the activity of another membrane protein in the
vicinity of TRPC6, such as an enzyme that affects phos-
phoinositide levels. Finally, TRPC6 has been reported to
be activated by membrane deformation [68], though this
has been disputed [69]. One could hypothesize that
SNF8 may act to recruit ESCRT-II to TRPC6, and alter
TRPC6 function through local convex deformation of
the membrane [70]. Further understanding the mechan-
ism whereby SNF8 enhances TRPC6 currents will be the
goal of future investigations.
Conclusion
This work shows that: 1. SNF8 is a potential binding
partner of TRPC6, 2. overexpression of SNF8 enhances
both wild-type and mutant TRPC6 current densities,
and 3. modulating SNF8 expression levels affects
NFAT activation downstream of gain-of-function, FSGS-
associated TRPC6 mutations. The mechanism for regu-
lating channel activity is not mediated by changes in
global cell surface expression or recruitment into lipid
rafts. Taken together, these results identify SNF8 as a
potent modulator of the TRPC6 channel.
Methods
Plasmids and reagents
The human TRPC6 coding sequence, with or without
mutations as outlined in the text, and containing an
amino-terminal FLAG tag sequence, was cloned into
pcDNA4/TO/myc-HIS B (Clontech) using standard
PCR-based techniques. Similarly, full-length human
TRPC6 carrying an amino-terminal HA tag was amplified
by PCR and subcloned into pcDNA3.1. The HA-SNF8
expression plasmid was a gift from C. Bucci [71]. The
Matchmaker Two-Hybrid System and S. cerevisiae Y187
pre-transformed with a human kidney cDNA library were
purchased from Clontech (Palo Alto, CA). The dual luci-
ferase assay kit and reporter vectors pGL4.30 and
pGL4.74 were obtained from Promega. Affinity purified
rabbit anti-TRPC6 polyclonal antibody was purchased
from Chemicon, anti-FLAG M2 monoclonal antibody and
anti-FLAG rabbit polyclonal antibodies were purchased
from Sigma, rabbit anti-GFP polyclonal antibody and
mouse anti-HA monoclonal antibody were purchased
from Abcam Inc, and rabbit anti-HA monoclonal anti-
body (C29F4) was purchased from Cell Signaling Tech-
nologies. Anti-SNF8 rabbit polyclonal antibody was the
kind gift of Dr. H. Stenmark [36]. Anti-caveolin-1 mouse
monoclonal antibody (clone 2297) was obtained from BD
Biosciences.
Yeast two-hybrid screen
cDNA encoding residues 1 through 406 of TRPC6 (wild-
type N-terminal domain) was used as bait and cloned
in-frame with GAL4 DNA-binding domain in the vector
pGBKT7-BD and transformed into yeast strain AH109.
The bait strain was mated to Y187 yeast strain pre-
transformed with a commercially available human kid-
ney cDNA library cloned into pACT2-AD vector
according to the manufacturer’s protocol (Clontech).
Based on mating efficiency, 1 × 10
6 clones were
screened. Mated yeast cells were grown on high-
stringency selection plates (SD-Leu, Trp, Ade, His) and
positive colonies were further verified by growth on
high-stringency plates supplemented with X-α-gal as a
test for β-galactosidase activity. pACT2-AD plasmids
containing library inserts from positive colonies were
isolated and transformed into DH5α derived E. coli
(New England Biolabs). Plasmids were then isolated
A
Control
WB: FLAG M2
SNF8 OEx
WB: Caveolin-1
SNF8 OEx
WB: HA
SNF8 OEx
WB: FLAG M2
Control
WB: Caveolin-1
Fraction 17 8 6 5 4 3 2
Fraction 1 7 8 6 5 4 3 2
B
Figure 8 Detergent-resistant membrane preparation. M1R
cells stably expressing TRPC6 were transiently transfected with
control vector (A) or HA-SNF8 expression construct (B). Triton X-100
detergent resistant membranes were separated from other
proteins by sucrose gradient centrifugation, and the abundance of
FLAG-TRPC6 and HA-SNF8 in each fraction analyzed by Western blot.
Caveolin-1 represents a marker of lipid rafts. Fraction 1 represents
the top of the gradient.
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NT alignment algorithm from NCBI.
To confirm the interaction, the full-length SNF8 cod-
ing sequence was cloned inframe into the pGAD-T7
plasmid and the resulting plasmid transformed into
Y187 strain yeast. The resulting strain was mated with
AH109 bait strain harboring pGBKT7 with wild-type
TRPC6 N-terminal sequences or the TRPC6 C-terminal
domain (corresponding to amino acids 726-931). The
resulting diploids were tested for positive interaction by
growth on high-stringency plates.
Cell culture and luciferase assays
Cells stably expressing the M1 muscarinic acetylcholine
receptor and either wild-type, R895C or E897K TRPC6
under a tetracycline-inducible promoter were generated
from T-Rex-293 cells (Invitrogen), as previously
described [38]. Stable cell lines were induced to express
TRPC6 for 24 hours prior to lysis by adding tetracycline
to a 1 μg/ml final concentration in culture medium.
Luciferase assays were carried out essentially as previ-
ously described [38] using the dual luciferase reporter
assay (DLR; Roche) using a Veritas microplate lumin-
ometer (Turner Biosystems). All conditions were tested
in triplicate and results normalized to the Renilla lucifer-
ase internal control.
RNA interference
SNF8 was knocked down using short hairpin-expressing
double-stranded oligonucleotides cloned into pcDNA
6.2-GW/EmGFP-miR plasmids (BLOCK-iT™ Pol II miR
RNAi Expression Vector Kit, Invitrogen). A specific
shRNA sequence against SNF8 (sense 5
0-TGACTTCG
[CC]CAATGTCAGTCAA-3
0 and antisense 5
0-TTGACT
GACATCCTGGGCGAA-3
0), and a scrabbled control
sequence, were obtained from Invitrogen and cloned
into the plasmid. Knock-down efficiency was deter-
mined by transient transfection of M1R cells with either
SNF8 or control plasmid, followed by FACS sorting for
GFP expression to isolate the transfected cells after 48
hrs. SNF8 expression in sorted cells was assessed by
immunbloting for SNF8.
To assess the effect of SNF8 knock-down on NFAT-
mediated transcription, cells were transfected with the
indicated shRNA expression vector and luciferase re-
porter plasmids using Fugene 6. 24 hours after transfec-
tion, TRPC6 expression was induced where indicated by
the addition of tetracycline (1μg/ml final concentration)
to the media. After an additional 24 hours, cells were
lysed and processed for dual luciferase reporter assay.
Immunoprecipitation and Immunoblotting
Transfected cells were rinsed once in phosphate buffered
saline and lysed in modified RIPA lysis buffer (50 mM
Tris, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate supplemented with Complete protease in-
hibitor cocktail (Roche)). After clearing lysates by centri-
fugation at 14,000 RPM for 15 minutes at 4ºC,
supernatants were incubated with 30 μlo fF L A GM 2
agarose slurry (Sigma-Aldrich), and incubated with con-
stant agitation at 4ºC for 2-3 hours. Immunoprecipitated
complexes were washed three times with lysis buffer and
eluted off of the beads by boiling in SDS-sample loading
buffer.
Cell lysates and immunoprecipitated materials were
separated by SDS-PAGE and transferred to PVDF mem-
brane (Bio-Rad). The membrane was blocked with 5% non-
fat milk in PBST (PBS with 0.05% Tween-20) for 1 hour
at room temperature, followed by overnight incubation
in 1:1000 anti-TRPC6, 1:500 anti-HA, 1:500 FLAG M2,
or 1:200 anti-SNF8 antibody in 5% non-fat milk PBST.
After three washes in PBST, blots were incubated with
the appropriate secondary antibody conjugated to HRP
(Pierce) in PBST at room temperature, followed by de-
tection with SuperSignal West Pico chemiluminescent
substrate (Pierce).
Fluorescence microscopy
Cells stably expressing wild-type TRPC6 under a tetra-
cycline inducible promoter were grown on collagen I
coated glass coverslips and transfected with plasmid
encoding for HA-SNF8 using Fugene6 followed by
treatment with tetracycline to induce FLAG-TRPC6.
24 hours after inducing TRPC6 expression, cells were
washed with PBS, fixed in 2% paraformaldehyde, 4% su-
crose in PBS, and permeabilized with 0.3% Triton X-100
in PBS. Nonspecific binding sites were blocked using
blocking solution (2% bovine serum albumin, 2% fetal
calf serum, 0.2% fish gelatin). Cells were incubated with
1:200 anti-FLAG M2 antibody and 1:1600 anti-HA
rabbit monoclonal antibody, followed by Alexa488 con-
jugated goat anti-mouse and Cy3 conjugated goat anti-
rabbit secondary antibody (Jackson ImmunoResearch),
and mounted on slides with ProLong Gold antifade re-
agent (Invitrogen). Images were taken using a Zeiss LSM
510 confocal microscope.
Electrophysiology
Patch-clamp electrophysiology (Axopatch 200B ampli-
fier, Axon Instruments, CA) was performed in the whole-
cell configuration. Briefly, HEK293T cells (American
Type Culture Collection, VA) were plated on
glass coverslips at low density and placed in the
recording chamber. The patch pipettes with resistances
of 3–4M Ω were pulled from borosilicate glass with a P-
97 puller (Sutter Instrument) and filled with a solution
containing (in mM): 135 CH3SO3Cs, 10 CsCl, 3 MgATP,
0.2 NaGTP, 0.2 EGTA, 0.13 CaCl2, and 10 HEPES,
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mM): 135 CH3SO3Na, 5 CsCl, 2 CaCl2, 1 MgCl2, 10
HEPES, and 10 Glucose, pH 7.4 with NaOH. Carbachol
(100 μM) or 1-oleoyl-2-acetyl-sn-glycerol (OAG, 10 μM)
was applied to the bath solution. Whole-cell currents
were recorded from –100 mV to 100 mV voltage ramps
over 150 ms and a holding potential of 0 mV. All data
were acquired at room temperature and analyzed using
pClamp 10 (Axon Instruments, CA). Statistical analysis
was done using one-way ANOVA Fisher’s LSD test, and
p values <0.05 were considered significant.
Surface biotinylation
Cells were surface biotinylated on ice using Sulfo-NHS-
SS-biotin (Pierce) 48 hours after transfection, essentially
as previously described [38], followed by lysis in modi-
fied RIPA buffer. Lysates were incubated with streptavi-
din beads (Pierce) at 4°C. The streptavidin beads were
extensively washed and bound material was eluted and
analyzed by SDS-PAGE electrophoresis followed by
Western blot analysis.
Lipid raft preparation
M1R cells stably expressing FLAG-tagged TRPC6 were
transfected with control or HA-SNF8 expression con-
structs. 48 hours after transfection, cells were processed
using a protocol modified from Alicia et al [54]. Briefly,
cells were washed in ice cold PBS, scraped off of plates
in PBS and lysed in 1% Triton X-100 in MES buffer
(25mM MES, pH 6.5, 150mM NaCl, 2mM EDTA com-
plemented with protease inhibitors) on ice for 20 minutes.
Lysates were further homogenized in a glass homo-
genizer with the loose fitting piston, then mixed with an
equal volume of 85% (w/v) sucrose in MES buffer.
Lysates were overlayed with 4mls of 40% sucrose in
MES buffer followed by 4mls of 5% sucrose in MES buf-
fer. Lysates were spun at 175,000x g for 24 hours in an
SW41 Ti rotor. Eight 1.5 ml fractions were obtained by
aspiration starting at the top of the gradient. Aliqouts of
each fraction were combined with 4x sample loading
buffer with β-mercaptoethanol and analyzed by Western
blot as above.
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